Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was downgraded by Citigroup Inc. from a “neutral” rating to a “sell” rating in a research report issued on Monday.

A number of other equities research analysts also recently issued reports on RARE. Jefferies Group set a $109.00 price target on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Sunday, September 18th. Canaccord Genuity set a $103.00 price target on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Friday. Zacks Investment Research downgraded shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday. Piper Jaffray Cos. set a $82.00 price target on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, August 9th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating and set a $101.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of “Buy” and an average price target of $94.70.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 82.06 on Monday. The company’s market cap is $3.35 billion. The stock’s 50 day moving average is $66.41 and its 200-day moving average is $63.72. Ultragenyx Pharmaceutical has a 52 week low of $46.52 and a 52 week high of $117.12.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, November 7th. The biopharmaceutical company reported ($1.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.53) by $0.11. During the same period in the previous year, the company posted ($1.03) EPS. On average, equities analysts anticipate that Ultragenyx Pharmaceutical will post ($6.14) earnings per share for the current year.

In related news, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction dated Friday, October 14th. The shares were sold at an average price of $63.02, for a total value of $1,260,400.00. Following the transaction, the chief executive officer now owns 480,632 shares of the company’s stock, valued at approximately $30,289,428.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Shalini Sharp sold 24,000 shares of the firm’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $71.20, for a total transaction of $1,708,800.00. Following the completion of the transaction, the chief financial officer now directly owns 69,387 shares in the company, valued at approximately $4,940,354.40. The disclosure for this sale can be found here. 10.10% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of RARE. Pacer Advisors Inc. bought a new position in Ultragenyx Pharmaceutical during the second quarter valued at approximately $100,000. First Mercantile Trust Co. increased its position in Ultragenyx Pharmaceutical by 1.7% in the third quarter. First Mercantile Trust Co. now owns 2,339 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 39 shares in the last quarter. Springbok Capital Management LLC bought a new position in Ultragenyx Pharmaceutical during the first quarter valued at approximately $189,000. Prudential Financial Inc. bought a new position in Ultragenyx Pharmaceutical during the third quarter valued at approximately $245,000. Finally, DIAM Co. Ltd. bought a new position in Ultragenyx Pharmaceutical during the second quarter valued at approximately $177,000. 93.01% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.